Commercialization Diligence Clause Samples

The Commercialization Diligence clause requires a party, typically a licensee, to actively and consistently pursue the development, marketing, and sale of a licensed product or technology. In practice, this clause may set specific milestones, reporting obligations, or performance standards that the licensee must meet to demonstrate ongoing efforts toward commercialization. Its core function is to ensure that the licensed intellectual property is not left idle and that both parties benefit from the agreement, addressing the risk of inactivity or underperformance by the licensee.
POPULAR SAMPLE Copied 1 times
Commercialization Diligence. Upon receipt of the Marketing Authorization for a Licensed Product in the Field in a given Region in the Territory, Lian (directly, or through its Affiliates, Sublicensees or contractors) will use Commercially Reasonable Efforts to Commercialize such Licensed Product in the Field in such Region in the Territory. Lian will have sole decision-making authority and discretion with respect to Commercializing the Licensed Product in the Field in the Territory. [***].
Commercialization Diligence. Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.
Commercialization Diligence. Dermavant shall, and shall ensure that each Responsible Party shall, use Commercially Reasonable Efforts to Commercialize the Product in the United States and each other jurisdiction in which Marketing Approval has been obtained and for each Indication for which Marketing Approval has been obtained, in each case taking into account the CRE Considerations.
Commercialization Diligence. Hansoh shall be responsible for, and shall use Commercially Reasonable Efforts to Commercialize each Licensed Product in the Field in each region in the Territory, including the timely performance of all activities set forth in the Commercialization Plan for such Licensed Product, at its sole cost and expense. Hansoh commits to utilize at least [***] ([***]) [***] for the first Licensed Product indicated for NMOSD, and to expend such resources comparable with Hansoh’s other products for the promotion and sales investments of Licensed Products. The activities of Hansoh’s Affiliates and sublicensees shall be attributed to Hansoh for the purposes of evaluating Hansoh’s fulfillment of the obligations set forth in this Section 7.1. (a) Hansoh shall use Commercially Reasonable Efforts to Commercialize the Licensed Product in the Territory to maximize the commercial return. Such efforts shall include marketing, promoting and selling the Licensed Product in a diligent sustained manner consistent with the standard practices of the pharmaceutical industry and as directed by the JCC. Hansoh shall establish and consistently seek to achieve specific and meaningful sales goals and allocate sufficient resources designed to meet such objectives, including, but not limited to, fielding, training (including any reasonably necessary medical education) and supervising a sales force (including an appropriate management structure) reasonably necessary for Hansoh to perform its commercialization obligations hereunder. Hansoh’s Commercialization obligations shall include, but not be limited to, the following: (i) [***]. (ii) On an indication-by-indication and region-by-region basis, [***]. (b) Hansoh shall have the final decision-making authority in relation to the pricing of the Licensed Product in the Territory; provided that Hansoh shall use good faith in setting pricing of the Licensed Product (containing Licensed Compound as its sole API) to maximize the commercial return of the Licensed Product (containing Licensed Compound as its sole API) and [***].
Commercialization Diligence. Licensee shall be responsible for, and shall use Commercially Reasonable Efforts to Commercialize each Licensed Product in the Field in each Region in the Territory, including the timely performance of all activities set forth in the Commercialization Plan for such Licensed Product, at its sole cost and expense.
Commercialization Diligence. Licensee shall use Commercially Reasonable Efforts (itself or with or through its Affiliates and/or Sublicensees) to Commercialize each Licensed Product in each indication in each Major Market in which Market Approval had been granted for such Licensed Product for such indication.
Commercialization Diligence. Subject to Cardiome’s receipt of access to a complete electronic copy of SteadyMed’s New Drug Application for Product and Infusion set in the Field as filed with the FDA and the required stability data for Product described below in this Section 6.3, Cardiome shall use Commercially Reasonable Efforts: (a) to obtain and maintain Regulatory Approvals in at least the Major Markets; (b) to obtain and maintain required Pricing Approvals in at least the Major Markets; (c) to initiate commercial sale of Supplied Items in each Major Market within six (6) months after receipt of Regulatory Approval and any required Pricing Approvals in such Major Market, and thereafter to Commercialize, and maximize Net Sales of, Supplied Items in the Field in such Major Market; and (d) otherwise to conduct material Commercialization Plan activities substantially in accordance with the timeline set forth in the Commercialization Plan. Without limiting the generality of the foregoing, no later than six (6) months after the later of (i) Cardiome’s receipt of access to a complete electronic copy of SteadyMed’s New Drug Application for Product as filed with the FDA and (ii) Cardiome’s receipt from SteadyMed of 12 months of stability data for Product, Cardiome shall file a Regulatory Application with each of the EMA and the applicable national Regulatory Authority in Canada. For clarity, SteadyMed shall be solely responsible for conducting the activities necessary to generate 12 months of stability data for Product, at SteadyMed’s sole cost.
Commercialization Diligence. ZEO shall have the sole discretion and control over the Commercialization of, shall be solely responsible for, and shall use commercially reasonable efforts to Commercialize, the Licensed Products in the Field in the Territory and any other commercialization rights that may be granted to ZEO pursuant to a written amendment or separate agreement contemplated by Section 3.4 at its sole cost and expense.
Commercialization Diligence. (a) Prior to Submission of First BLA. For each Product under Development, prior to the submission of the first BLA to the first Regulatory Authority in the Territory, Green Cross shall submit to the JSC a written summary plan for the Commercialization for each such Product under Development. Thereafter, Green Cross shall regularly report on its Commercialization activities at meetings of the JSC or, if formed, the Joint Commercialization Committee. Such reports shall cover subject matter at a level of detail similar to that which Green Cross affords to its senior executives with respect to similar Green Cross products. All such plans and information shall be presented for discussion purposes, and Green Cross agrees to consider in good faith any comments or suggestions MacroGenics may make with respect to Commercialization of Products.
Commercialization Diligence. Each Party, directly and/or with or through Affiliates or Sublicensees, shall use Commercially Reasonable Efforts to perform the activities allocated to it in the Co-Development Product Commercialization Plan and/or by the JSC in order to Commercialize the Co-Development Products in the Co-Development Field in the Territory.